Product Description
Intermediate of herbicides sulfonone and nitrosulfonone
AI Product Description
*The following content is generated by AI and is for reference only.
Terazosin hydrochloride is a widely prescribed pharmaceutical agent belonging to the class of alpha-1 adrenergic receptor blockers. Its chemical formula is C19H25N5O4·HCl, and it is universally identified by the CAS Registry Number 78330-56-0. This white to off-white crystalline powder is highly soluble in water and serves as the hydrochloride salt form of terazosin, ensuring optimal stability and bioavailability for oral administration. The primary therapeutic application of Terazosin hydrochloride lies in the management of hypertension, where it effectively lowers blood pressure by relaxing vascular smooth muscle. By selectively blocking alpha-1 receptors on arterial and venous walls, it inhibits vasoconstriction induced by norepinephrine, thereby reducing peripheral vascular resistance and improving cardiac output. Beyond its antihypertensive properties, this medication is extensively utilized to treat symptoms associated with benign prostatic hyperplasia (BPH). In BPH patients, it relaxes the smooth muscles of the prostate gland and bladder neck, facilitating improved urine flow and alleviating urinary obstruction, frequency, and urgency. The drug is typically administered once daily due to its long half-life, which supports consistent plasma concentrations. Common side effects may include dizziness, headache, fatigue, and orthostatic hypotension, particularly during the initial dose titration phase. Clinicians often advise patients to take the first dose at bedtime to minimize the risk of syncope. As a generic alternative to brand-name formulations, Terazosin hydrochloride offers a cost-effective solution for managing chronic cardiovascular and urological conditions globally. Its versatility makes it a cornerstone therapy in modern pharmacology for patients requiring dual control of blood pressure and lower urinary tract symptoms. Continuous monitoring is essential to ensure efficacy and safety, especially when combined with other antihypertensives or phosphodiesterase inhibitors used for erectile dysfunction.